These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 19920004)

  • 1. Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study.
    Levine RJ; Vatten LJ; Horowitz GL; Qian C; Romundstad PR; Yu KF; Hollenberg AN; Hellevik AI; Asvold BO; Karumanchi SA
    BMJ; 2009 Nov; 339():b4336. PubMed ID: 19920004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First trimester serum angiogenic and anti-angiogenic factors in women with chronic hypertension for the prediction of preeclampsia.
    Nzelu D; Biris D; Karampitsakos T; Nicolaides KK; Kametas NA
    Am J Obstet Gynecol; 2020 Apr; 222(4):374.e1-374.e9. PubMed ID: 31705883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal serum levels of soluble fms-like tyrosine kinase-1 and placental growth factor at 20 and 28 weeks of gestational age and the risk of spontaneous preterm birth.
    Sovio U; Gaccioli F; Cook E; Charnock-Jones DS; Smith GCS
    Am J Obstet Gynecol; 2023 Aug; 229(2):164.e1-164.e18. PubMed ID: 36758709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of imminent preeclampsia at 35-37 weeks gestation.
    Ciobanu A; Wright A; Panaitescu A; Syngelaki A; Wright D; Nicolaides KH
    Am J Obstet Gynecol; 2019 Jun; 220(6):584.e1-584.e11. PubMed ID: 30738886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human chorionic gonadotropin, angiogenic factors, and preeclampsia risk: a nested case-control study.
    Asvold BO; Eskild A; Vatten LJ
    Acta Obstet Gynecol Scand; 2014 May; 93(5):454-62. PubMed ID: 24575980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of urinary soluble endoglin in the diagnosis of pre-eclampsia: comparison with soluble fms-like tyrosine kinase 1 to placental growth factor ratio.
    Buhimschi CS; Baumbusch MA; Dulay AT; Lee S; Wehrum M; Zhao G; Bahtiyar MO; Pettker CM; Ali UA; Funai EF; Buhimschi IA
    BJOG; 2010 Feb; 117(3):321-30. PubMed ID: 19943826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessment.
    Maraka S; Mwangi R; McCoy RG; Yao X; Sangaralingham LR; Singh Ospina NM; O'Keeffe DT; De Ycaza AE; Rodriguez-Gutierrez R; Coddington CC; Stan MN; Brito JP; Montori VM
    BMJ; 2017 Jan; 356():i6865. PubMed ID: 28122781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Thyroid hormone changes in women with pre-eclampsia and its relationship with the presence of pre-eclampsia].
    Zhou J; Du J; Ma B; Liu X; Qiu H; Li J; Wang X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Feb; 49(2):109-13. PubMed ID: 24739642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid-stimulating hormone, anti-thyroid antibodies, and pregnancy outcomes.
    Plowden TC; Schisterman EF; Sjaarda LA; Perkins NJ; Silver R; Radin R; Kim K; Galai N; DeCherney AH; Mumford SL
    Am J Obstet Gynecol; 2017 Dec; 217(6):697.e1-697.e7. PubMed ID: 28917612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia.
    Saleh L; van den Meiracker AH; Geensen R; Kaya A; Roeters van Lennep JE; Duvekot JJ; Verdonk K; Steegers EAP; Russcher H; Danser AHJ; Visser W
    Ultrasound Obstet Gynecol; 2018 Jun; 51(6):751-757. PubMed ID: 28600845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenic markers and their longitudinal change for predicting adverse outcomes in pregnant women with chronic hypertension.
    Binder J; Kalafat E; Palmrich P; Pateisky P; Khalil A
    Am J Obstet Gynecol; 2021 Sep; 225(3):305.e1-305.e14. PubMed ID: 33812812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between maternal thyroid function and risk of gestational hypertension and pre-eclampsia: a systematic review and individual-participant data meta-analysis.
    Toloza FJK; Derakhshan A; Männistö T; Bliddal S; Popova PV; Carty DM; Chen L; Taylor P; Mosso L; Oken E; Suvanto E; Itoh S; Kishi R; Bassols J; Auvinen J; López-Bermejo A; Brown SJ; Boucai L; Hisada A; Yoshinaga J; Shilova E; Grineva EN; Vrijkotte TGM; Sunyer J; Jiménez-Zabala A; Riaño-Galan I; Lopez-Espinosa MJ; Prokop LJ; Singh Ospina N; Brito JP; Rodriguez-Gutierrez R; Alexander EK; Chaker L; Pearce EN; Peeters RP; Feldt-Rasmussen U; Guxens M; Chatzi L; Delles C; Roeters van Lennep JE; Pop VJM; Lu X; Walsh JP; Nelson SM; Korevaar TIM; Maraka S
    Lancet Diabetes Endocrinol; 2022 Apr; 10(4):243-252. PubMed ID: 35255260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia.
    Powers RW; Roberts JM; Cooper KM; Gallaher MJ; Frank MP; Harger GF; Ness RB
    Am J Obstet Gynecol; 2005 Jul; 193(1):185-91. PubMed ID: 16021077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting.
    Zeisler H; Llurba E; Chantraine FJ; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Schoedl M; Grill S; Hund M; Verlohren S
    Ultrasound Obstet Gynecol; 2019 Mar; 53(3):367-375. PubMed ID: 30014562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A longitudinal analysis of angiotensin II type 1 receptor antibody and angiogenic markers in pregnancy.
    Aggarwal S; Sunderland N; Thornton C; Xu B; Hennessy A; Makris A
    Am J Obstet Gynecol; 2017 Feb; 216(2):170.e1-170.e8. PubMed ID: 27793555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
    Holme AM; Roland MC; Henriksen T; Michelsen TM
    Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia.
    Lynch AM; Murphy JR; Gibbs RS; Levine RJ; Giclas PC; Salmon JE; Holers VM
    BJOG; 2010 Mar; 117(4):456-62. PubMed ID: 20074261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predelivery placenta-associated biomarkers and computerized intrapartum fetal heart rate patterns.
    Bowe S; Mitlid-Mork B; Gran JM; Distante S; Redman CWG; Staff AC; Georgieva A; Sugulle M
    AJOG Glob Rep; 2023 Feb; 3(1):100149. PubMed ID: 36647548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
    Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
    N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.